Malignant fibrous histiocytoma developing in irradiated sacral chordoma.
Malignant fibrous histiocytoma (MFH), arising at the site of a sacral chordoma 8 years after massive radiotherapy, is described. Initially, the patient received 7000 rad to the sacral area and, on recurrence, 5 years later, an additional 4000 rad. Two years later, a sacral mass was noted again. Biopsy then revealed MFH; chest x-ray showed multiple lung metastases. A combination chemotherapy, consisting of cyclophosphamide, vincristine, adriamycin (doxorubicin), and DTIC, resulted in a 6 month partial response. Subsequently, the patient died because of progressive metastatic disease. At autopsy, 8 years after diagnosis, both the sacral lesion and the lung metastases proved to be MFH, and no residual chordoma was found.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D002817:Chordoma / Q000473:pathology / Q000532:radiotherapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D018219:Histiocytoma, Benign Fibrous / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy / Q000473:pathology*; D011878:Radiotherapy / Q000009:adverse effects*; D012445:Sacrococcygeal Region; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide